Market Overview The global market for Active Pharmaceutical Ingredient (API) Contract Development & Manufacturing Organization (CDMO) reached USD 92 Billion in 2022 and is projected to achieve a revenue Compound Annual Growth Rate (CAGR) of 7% throughout the forecast period. Key drivers of market revenue growth include the increasing prevalence of chronic diseases such as cancer, cardiovascular conditions, and diabetes, along with a heightened demand for enhanced therapies. Additionally, the market is propelled by the growing emphasis on cost-effective manufacturing and the need for specialized expertise in drug development, which fosters demand for API contract development and manufacturing services.
Get a sample copy of the Active Pharmaceutical Ingredient (API) Contract Development & Manufacturing Organization Market report: https://www.reportsanddata.com/download-free-sample/6023
Furthermore, the trend towards outsourcing drug research and manufacturing operations is contributing to the demand for API CDMO services. Outsourcing expedites the medication development process, reduces overhead costs, and allows pharmaceutical companies to focus on their core competencies. Moreover, it grants clients access to specialized knowledge in the design and production of advanced pharmaceuticals, thus fueling market revenue growth.
Introduction of innovative technologies such as continuous production, Process Analytical Technology (PAT), and Artificial Intelligence (AI) is anticipated to accelerate drug development and lower manufacturing costs. High-potency APIs (HPAPIs) are witnessing high demand, driving market revenue growth due to the specialized knowledge required for their production.
Additionally, stringent regulatory requirements for pharmaceutical quality and safety, coupled with a rising emphasis on Good Manufacturing Practices (GMP), are spurring demand for reliable and skilled CDMO partners, further boosting market revenue.
However, the API CDMO industry has been impacted by the COVID-19 pandemic, resulting in shortages of APIs and pharmaceuticals due to disruptions in global manufacturing and supply chains. Nevertheless, the pandemic has led to increased investment in drug development and production activities, expected to drive market revenue growth.
Key Insights Manufacturing Type Analysis: The global API CDMO market is segmented into contract manufacturing and in-house manufacturing. Contract manufacturing, which involves outsourcing API production to third-party organizations, is expected to hold the largest revenue share during the forecast period. This segment facilitates pharmaceutical companies to focus on core competencies while receiving cost-effective, high-quality API production services from CDMOs.
Conversely, in-house manufacturing is projected to exhibit the fastest revenue CAGR, driven by the rising demand for high-quality and customized APIs. In-house manufacturing allows pharmaceutical companies to maintain control over the production process, quality, and timelines, albeit requiring significant investments and continuous monitoring.
Type of Synthesis Analysis: The market is segmented into biotech synthesis and synthetic chemical API synthesis. Synthetic chemical API synthesis, which accounted for the largest revenue share in 2021, is expected to maintain its dominance owing to the increasing demand for synthetic APIs in generic drug production and API development outsourcing. Conversely, biotech synthesis is forecasted to register the highest revenue growth rate, driven by the growing adoption of Biologics and Biosimilars in disease treatment.
Regional Analysis: North America is anticipated to hold the largest revenue share, driven by the demand for innovative drugs and the outsourcing trend to specialized CDMOs. Europe is expected to follow, supported by a well-established pharmaceutical industry and stringent regulatory guidelines. Asia Pacific is projected to witness the fastest revenue CAGR, attributed to its emergence as a pharmaceutical manufacturing hub, low-cost labor, government initiatives, and increasing contract manufacturing organizations.
Competitive Landscape: The API CDMO market is highly competitive, with several large and medium-sized players dominating the market revenue. Major companies are implementing strategies such as mergers & acquisitions and strategic agreements to enhance their product offerings and market presence. Key players include Thermo Fisher Scientific Inc., Lonza Group AG, Cambrex Corporation, among others.
Strategic Developments: Thermo Fisher Scientific Inc. acquired Henogen S.A. to strengthen its biologics development and manufacturing capabilities. Cambrex Corporation was acquired by Permira to support its growth in the life sciences sector. Lonza Group AG partnered with Moderna to support the manufacturing of the COVID-19 vaccine. Segmentation and Customization: The report offers segmentation based on various parameters such as manufacturing type, type of synthesis, type of drug, therapeutic application, end-user, and region. Additionally, customization options are available to tailor the report according to specific requirements, offering 10 hours of free customization and expert consultation.
Explore Trending Reports:
Pressure Sensitive Adhesives Market-https://www.reportsanddata.com/report-detail/pressure-sensitive-adhesive-market
Construction Adhesive Market-https://www.reportsanddata.com/report-detail/construction-adhesive-market
Basalt Fiber Market-https://www.reportsanddata.com/report-detail/basalt-fiber-market
Ammonium Nitrate Market-https://www.reportsanddata.com/report-detail/ammonium-nitrate-market
Roofing Systems Market-https://www.reportsanddata.com/report-detail/roofing-systems-market
Polyimide Films Market-https://www.reportsanddata.com/report-detail/polyimide-film-market
Plastic Fasteners Market-https://www.reportsanddata.com/report-detail/plastic-fasteners-market
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/6023
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek